Leading doctors, advocacy groups, medical organizations and U.S. TB programs commend Sanofi U.S. commitment to reduce the price of tuberculosis drug rifapentine.
The letter warmly welcomes the December 10, 2013 announcement that Sanofi U.S. will lower the price of rifapentine to $32.00 per 32-tablet blister pack in January 2014 and follows statements made by CRAG and TAG in the wake of Sanofi's announcement last week.
"This price decrease will make TB treatment more cost-effective for U.S. TB programs and simplify treatment for patients. With this price reduction, Sanofi U.S. is taking concrete steps to bridge the gap between TB research and practice, and is setting a laudable example that other drug companies should follow."
The letter also commends "Sanofi U.S.’s statement that collaborations with TB centers, the National Tuberculosis Controller’s Association, the U.S. Centers for Disease Control and Prevention (CDC) and TB community groups are critical moving forward.”
Two open letters were sent to the company this year demanding a price reduction of rifapentine and continued support for its development through research conducted by the CDC's Tuberculosis Trials Consortium (read here and here).
To view the letter, click here.